Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine development

Cytokine and Growth Factor Reviews

Volumn 23, Issue 4-5, 2012, Pages 193-206

  Keating, Sheila M ^a,b   Jacobs, Evan S ^a   Norris, Philip J ^a,b  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemokine; Cytokine; HIV; Immune activation; Vaccine

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 27; INTERLEUKIN 6; INTERLEUKIN 7; MONOCYTE CHEMOTACTIC PROTEIN 1; NEOPTERIN; NONOXINOL 9; PEGINTERFERON ALPHA; RECOMBINANT INTERLEUKIN 2; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADJUVANT THERAPY; ANTIBODY RESPONSE; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; COMORBIDITY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; CYTOKINE STORM; DISEASE ASSOCIATION; DISEASE MARKER; DRUG DESIGN; DRUG EFFICACY; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFLAMMATION; MIXED INFECTION; MUCOSAL IMMUNITY; NONHUMAN; ONSET AGE; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T CELL DEPLETION; VACCINATION; VIRUS INHIBITION; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMALS; CYTOKINES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY; INFLAMMATION MEDIATORS;

EID: 84864910464     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2012.05.006     Document Type: Article

References (198)

1. Letvin N.L., Daniel M.D., Sehgal P.K., Desrosiers R.C., Hunt R.D., Waldron L.M., et al. Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III. Science 1985, 230:71-73.
2. Zhang Z., Schuler T., Zupancic M., Wietgrefe S., Staskus K.A., Reimann K.A., et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 1999, 286:1353-1357.
3. Li Q., Duan L., Estes J.D., Ma Z.M., Rourke T., Wang Y., et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005, 434:1148-1152.
4. Benveniste O., Vaslin B., Le Grand R., Fouchet P., Omessa V., Theodoro F., et al. Interleukin 1 beta, interleukin 6, tumor necrosis factor alpha, and interleukin 10 responses in peripheral blood mononuclear cells of cynomolgus macaques during acute infection with SIVmac251. AIDS Research and Human Retroviruses 1996, 12:241-250.
5. Khatissian E., Tovey M.G., Cumont M.C., Monceaux V., Lebon P., Montagnier L., et al. The relationship between the interferon alpha response and viral burden in primary SIV infection. AIDS Research and Human Retroviruses 1996, 12:1273-1278.
6. Rosenberg Y.J., Cafaro A., Brennan T., Greenhouse J.G., Villinger F., Ansari A.A., et al. Virus-induced cytokines regulate circulating lymphocyte levels during primary SIV infections. International Immunology 1997, 9:703-712.
7. Zou W., Lackner A.A., Simon M., Durand-Gasselin I., Galanaud P., Desrosiers R.C., et al. Early cytokine and chemokine gene expression in lymph nodes of macaques infected with simian immunodeficiency virus is predictive of disease outcome and vaccine efficacy. Journal of Virology 1997, 71:1227-1236.
8. Cheret A., Le Grand R., Caufour P., Neildez O., Matheux F., Theodoro F., et al. RANTES, IFN-gamma, CCR1, and CCR5 mRNA expression in peripheral blood, lymph node, and bronchoalveolar lavage mononuclear cells during primary simian immunodeficiency virus infection of macaques. Virology 1999, 255:285-293.
9. Kanki P.J., Kurth R., Becker W., Dreesman G., McLane M.F., Essex M. Antibodies to simian T-lymphotropic retrovirus type III in African green monkeys and recognition of STLV-III viral proteins by AIDS and related sera. Lancet 1985, 1:1330-1332.
10. Silvestri G., Sodora D.L., Koup R.A., Paiardini M., O'Neil S.P., McClure H.M., et al. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 2003, 18:441-452.
11. Kornfeld C., Ploquin M.J., Pandrea I., Faye A., Onanga R., Apetrei C., et al. Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. Journal of Clinical Investigation 2005, 115:1082-1091.
12. Mandl J.N., Barry A.P., Vanderford T.H., Kozyr N., Chavan R., Klucking S., et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nature Medicine 2008, 14:1077-1087.
13. Harris L.D., Tabb B., Sodora D.L., Paiardini M., Klatt N.R., Douek D.C., et al. Downregulation of robust acute type I interferon responses distinguishes nonpathogenic simian immunodeficiency virus (SIV) infection of natural hosts from pathogenic SIV infection of rhesus macaques. Journal of Virology 2010, 84:7886-7891.
14. Bosinger S.E., Li Q., Gordon S.N., Klatt N.R., Duan L., Xu L., et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. Journal of Clinical Investigation 2009, 119:3556-3572.
15. Jacquelin B., Mayau V., Targat B., Liovat A.S., Kunkel D., Petitjean G., et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. Journal of Clinical Investigation 2009, 119:3544-3555.
16. Benveniste O., Vaslin B., Le Grand R., Cheret A., Matheux F., Theodoro F., et al. Comparative interleukin (IL-2)/interferon IFN-gamma and IL-4/IL-10 responses during acute infection of macaques inoculated with attenuated nef-truncated or pathogenic SICmac251 virus. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:3658-3663.
17. Fiebig E.W., Wright D.J., Rawal B.D., Garrett P.E., Schumacher R.T., Peddada L., et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003, 17:1871-1879.
18. Kelley C.F., Barbour J.D., Hecht F.M. The relation between symptoms, viral load, and viral load set point in primary HIV infection. Journal of Acquired Immune Deficiency Syndromes 2007, 45:445-448.
19. Abb J., Zachoval R., Zachoval V., Deinhardt F. HIV antigen, HIV antibody and serum interferon in a patient with encephalopathy. Infection 1987, 15:425-426.
20. Gaines H., von Sydow M.A., von Stedingk L.V., Biberfeld G., Bottiger B., Hansson L.O., et al. Immunological changes in primary HIV-1 infection. AIDS 1990, 4:995-999.
21. von Sydow M., Sonnerborg A., Gaines H., Strannegard O. Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. AIDS Research and Human Retroviruses 1991, 7:375-380.
22. Sinicco A., Biglino A., Sciandra M., Forno B., Pollono A.M., Raiteri R., et al. Cytokine network and acute primary HIV-1 infection. AIDS 1993, 7:1167-1172.
23. Biglino A., Sinicco A., Forno B., Pollono A.M., Sciandra M., Martini C., et al. Serum cytokine profiles in acute primary HIV-1 infection and in infectious mononucleosis. Clinical Immunology and Immunopathology 1996, 78:61-69.
24. Norris P.J., Pappalardo B.L., Custer B., Spotts G., Hecht F.M., Busch M.P. Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV type 1 infection. AIDS Research and Human Retroviruses 2006, 22:757-762.
25. Graziosi C., Gantt K.R., Vaccarezza M., Demarest J.F., Daucher M., Saag M.S., et al. Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:4386-4391.
26. Li Q., Smith A.J., Schacker T.W., Carlis J.V., Duan L., Reilly C.S., et al. Microarray analysis of lymphatic tissue reveals stage-specific, gene expression signatures in HIV-1 infection. Journal of Immunology 2009, 183:1975-1982.
27. Gasper-Smith N., Crossman D.M., Whitesides J.F., Mensali N., Ottinger J.S., Plonk S.G., et al. Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. Journal of Virology 2008, 82:7700-7710.
28. Stacey A.R., Norris P.J., Qin L., Haygreen E.A., Taylor E., Heitman J., et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. Journal of Virology 2009, 83:3719-3733.
29. Tobler L.H., Cameron M.J., Lanteri M.C., Prince H.E., Danesh A., Persad D., et al. Interferon and interferon-induced chemokine expression is associated with control of acute viremia in West Nile virus-infected blood donors. Journal of Infectious Diseases 2008, 198:979-983.
30. Lanteri M.C., O'Brien K.M., Purtha W.E., Cameron M.J., Lund J.M., Owen R.E., et al. Tregs control the development of symptomatic West Nile virus infection in humans and mice. Journal of Clinical Investigation 2009, 119:3266-3277.
31. Hicks D.R., Martin L.S., Getchell J.P., Heath J.L., Francis D.P., McDougal J.S., et al. Inactivation of HTLV-III/LAV-infected cultures of normal human lymphocytes by nonoxynol-9 in vitro. Lancet 1985, 2:1422-1423.
32. Roddy R.E., Zekeng L., Ryan K.A., Tamoufe U., Weir S.S., Wong E.L. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. New England Journal of Medicine 1998, 339:504-510.
33. Stafford M.K., Ward H., Flanagan A., Rosenstein I.J., Taylor-Robinson D., Smith J.R., et al. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998, 17:327-331.
34. Li Q., Estes J.D., Schlievert P.M., Duan L., Brosnahan A.J., Southern P.J., et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009, 458:1034-1038.
35. Abel K., Rocke D.M., Chohan B., Fritts L., Miller C.J. Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. Journal of Virology 2005, 79:12164-12172.
36. Roberts L., Passmore J.A., Mlisana K., Williamson C., Little F., Bebell L.M., et al. Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women. Journal of Infectious Diseases 2012, 205:194-203.
37. Bebell L.M., Passmore J.A., Williamson C., Mlisana K., Iriogbe I., van Loggerenberg F., et al. Relationship between levels of inflammatory cytokines in the genital tract and CD4+ cell counts in women with acute HIV-1 infection. Journal of Infectious Diseases 2008, 198:710-714.
38. Brenchley J.M., Schacker T.W., Ruff L.E., Price D.A., Taylor J.H., Beilman G.J., et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. Journal of Experimental Medicine 2004, 200:749-759.
39. Soghoian D.Z., Jessen H., Flanders M., Sierra-Davidson K., Cutler S., Pertel T., et al. HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Science Translational Medicine 2012, 4:123ra25.
40. Durudas A., Milush J.M., Chen H.L., Engram J.C., Silvestri G., Sodora D.L. Elevated levels of innate immune modulators in lymph nodes and blood are associated with more-rapid disease progression in simian immunodeficiency virus-infected monkeys. Journal of Virology 2009, 83:12229-12240.
41. Campillo-Gimenez L., Cumont M.C., Fay M., Kared H., Monceaux V., Diop O., et al. AIDS progression is associated with the emergence of IL-17-producing cells early after simian immunodeficiency virus infection. Journal of Immunology 2010, 184:984-992.
42. Roberts L., Passmore J.A., Williamson C., Little F., Bebell L.M., Mlisana K., et al. Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. AIDS 2010, 24:819-831.
43. Barcellini W., Rizzardi G.P., Poli G., Tambussi G., Velati C., Meroni P.L., et al. Cytokines and soluble receptor changes in the transition from primary to early chronic HIV type 1 infection. AIDS Research and Human Retroviruses 1996, 12:325-331.
44. Keating S.M., Golub E.T., Nowicki M., Young M., Anastos K., Crystal H., et al. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS 2011, 25:1823-1832.
45. Papagno L., Spina C.A., Marchant A., Salio M., Rufer N., Little S., et al. Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biology 2004, 2:E20.
46. Brenchley J.M., Karandikar N.J., Betts M.R., Ambrozak D.R., Hill B.J., Crotty L.E., et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 2003, 101:2711-2720.
47. Sheth P.M., Sunderji S., Shin L.Y., Rebbapragada A., Huibner S., Kimani J., et al. Coinfection with herpes simplex virus type 2 is associated with reduced HIV-specific T cell responses and systemic immune activation. Journal of Infectious Diseases 2008, 197:1394-1401.
48. Cassone A., Cauda R. Candida and candidiasis in HIV-infected subjects. Where commensalism, opportunistic behavior and frank pathogenicity lose their borders. AIDS 2012, [Epub ahead of print].
49. Breen E.C., Rezai A.R., Nakajima K., Beall G.N., Mitsuyasu R.T., Hirano T., et al. Infection with HIV is associated with elevated IL-6 levels and production. Journal of Immunology 1990, 144:480-484.
50. Kuller L.H., Tracy R., Belloso W., De Wit S., Drummond F., Lane H.C., et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Medicine 2008, 5:e203.
51. Poli G., Fauci A.S. The effect of cytokines and pharmacologic agents on chronic HIV infection. AIDS Research and Human Retroviruses 1992, 8:191-197.
52. Bollinger R.C., Quinn T.C., Liu A.Y., Stanhope P.E., Hammond S.A., Viveen R., et al. Cytokines from vaccine-induced HIV-1 specific cytotoxic T lymphocytes: effects on viral replication. AIDS Research and Human Retroviruses 1993, 9:1067-1077.
53. Bayard-McNeeley M., Doo H., He S., Hafner A., Johnson W.D., Ho J.L. Differential effects of interleukin-12, interleukin-15, and interleukin-2 on human immunodeficiency virus type 1 replication in vitro. Clinical and Diagnostic Laboratory Immunology 1996, 3:547-553.
54. Ferre A.L., Hunt P.W., Critchfield J.W., Young D.H., Morris M.M., Garcia J.C., et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 2009, 113:3978-3989.
55. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107:4781-4789.
56. Jansen C.A., De Cuyper I.M., Steingrover R., Jurriaans S., Sankatsing S.U., Prins J.M., et al. Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions. AIDS 2005, 19:1145-1154.
57. Byrnes A.A., Harris D.M., Atabani S.F., Sabundayo B.P., Langan S.J., Margolick J.B., et al. Immune activation and IL-12 production during acute/early HIV infection in the absence and presence of highly active, antiretroviral therapy. Journal of Leukocyte Biology 2008, 84:1447-1453.
58. Navikas V., Link J., Persson C., Olsson T., Hojeberg B., Ljungdahl A., et al. Increased mRNA expression of IL-6, IL-10, TNF-alpha, and perforin in blood mononuclear cells in human HIV infection. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1995, 9:484-489.
59. Iannello A., Boulassel M.R., Samarani S., Tremblay C., Toma E., Routy J.P., et al. HIV-1 causes an imbalance in the production of interleukin-18 and its natural antagonist in HIV-infected individuals: implications for enhanced viral replication. Journal of Infectious Diseases 2010, 201:608-617.
60. Conaldi P.G., Serra C., Dolei A., Basolo F., Falcone V., Mariani G., et al. Productive HIV-1 infection of human vascular endothelial cells requires cell proliferation and is stimulated by combined treatment with interleukin-1 beta plus tumor necrosis factor-alpha. Journal of Medical Virology 1995, 47:355-363.
61. Phillips A.N., Carr A., Neuhaus J., Visnegarwala F., Prineas R., Burman W.J., et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antiviral Therapy 2008, 13:177-187.
62. Currie P.F., Boon N.A. Immunopathogenesis of HIV-related heart muscle disease: current perspectives. AIDS 2003, 17(Suppl. 1):S21-S28.
63. Longo D.L., Steis R.G., Lane H.C., Lotze M.T., Rosenberg S.A., Preble O., et al. Malignancies in the AIDS patient: natural history, treatment strategies, and preliminary results. Annals of the New York Academy of Sciences 1984, 437:421-430.
64. Klein D., Hurley L.B., Quesenberry C.P., Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?. Journal of Acquired Immune Deficiency Syndromes 2002, 30:471-477.
65. Hsue P.Y., Hunt P.W., Sinclair E., Bredt B., Franklin A., Killian M., et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 2006, 20:2275-2283.
66. Triant V.A., Lee H., Hadigan C., Grinspoon S.K. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. The Journal of Clinical Endocrinology and Metabolism 2007, 92:2506-2512.
67. Malizia A.P., Cotter E., Chew N., Powderly W.G., Doran P.P. HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts. AIDS Research and Human Retroviruses 2007, 23:243-250.
68. Caccamo D., Pervez N.K., Marchevsky A. Primary lymphoma of the liver in the acquired immunodeficiency syndrome. Archives of Pathology and Laboratory Medicine 1986, 110:553-555.
69. O'Donnell M.P., Chao C.C., Gekker G., Modi K.S., Kasiske B.L., Keane W.F. Renal cell cytokine production stimulates HIV-1 expression in chronically HIV-1-infected monocytes. Kidney International 1998, 53:593-597.
70. Shah A., Singh D.P., Buch S., Kumar A. HIV-1 envelope protein gp120 up regulates CCL5 production in astrocytes which can be circumvented by inhibitors of NF-kappaB pathway. Biochemical and Biophysical Research Communications 2011, 414:112-117.
71. Neuhaus J., Jacobs D.R., Baker J.V., Calmy A., Duprez D., La Rosa A., et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. Journal of Infectious Diseases 2010, 201:1788-1795.
72. Moskowitz L., Hensley G.T., Chan J.C., Adams K. Immediate causes of death in acquired immunodeficiency syndrome. Archives of Pathology and Laboratory Medicine 1985, 109:735-738.
73. Fink L., Reichek N., Sutton M.G. Cardiac abnormalities in acquired immune deficiency syndrome. The American Journal of Cardiology 1984, 54:1161-1163.
74. Herskowitz A., Willoughby S.B., Baughman K.L., Schulman S.P., Bartlett J.D. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: a report of six cases. Annals of Internal Medicine 1992, 116:311-313.
75. Rodriguez E.R., Nasim S., Hsia J., Sandin R.L., Ferreira A., Hilliard B.A., et al. Cardiac myocytes and dendritic cells harbor human immunodeficiency virus in infected patients with and without cardiac dysfunction: detection by multiplex, nested, polymerase chain reaction in individually microdissected cells from right ventricular endomyocardial biopsy tissue. The American Journal of Cardiology 1991, 68:1511-1520.
76. Twu C., Liu N.Q., Popik W., Bukrinsky M., Sayre J., Roberts J., et al. Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathways. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:14386-14391.
77. Barbaro G., Di Lorenzo G., Soldini M., Giancaspro G., Grisorio B., Pellicelli A., et al. Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS (GISCA). Circulation 1999, 100:933-939.
78. Valcour V., Chalermchai T., Sailasuta N., Marovich M., Lerdlum S., Suttichom D., et al. CNS viral invasion and inflammation during acute HIV. Journal of Infectious Diseases 2012, [Epub ahead of print].
79. Sei Y., Vitkovic L., Yokoyama M.M. Cytokines in the central nervous system: regulatory roles in neuronal function, cell death and repair. Neuroimmunomodulation 1995, 2:121-133.
80. Leveque T., Le Pavec G., Boutet A., Tardieu M., Dormont D., Gras G. Differential regulation of gelatinase A and B and TIMP-1 and -2 by TNFalpha and HIV virions in astrocytes. Microbes and Infection/Institut Pasteur 2004, 6:157-163.
81. Pulliam L., Herndier B.G., Tang N.M., McGrath M.S. Human immunodeficiency virus-infected macrophages produce soluble factors that cause histological and neurochemical alterations in cultured human brains. Journal of Clinical Investigation 1991, 87:503-512.
82. Pitha P.M. Multiple effects of interferon on the replication of human immunodeficiency virus type 1. Antiviral Research 1994, 24:205-219.
83. Shirazi Y., Pitha P.M. Alpha interferon inhibits early stages of the human immunodeficiency virus type 1 replication cycle. Journal of Virology 1992, 66:1321-1328.
84. Bhagani S. Current treatment for chronic hepatitis C virus/HIV-infected individuals: the role of pegylated interferon-alpha and ribavirin. Current Opinion in HIV and AIDS 2011, 6:483-490.
85. Abrams D.I., Volberding P.A. Alpha interferon therapy of AIDS-associated Kaposi's sarcoma. Seminars in Oncology 1986, 13:43-47.
86. de Wit R., Schattenkerk J.K., Boucher C.A., Bakker P.J., Veenhof K.H., Danner S.A. Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma. Lancet 1988, 2:1214-1217.
87. Krown S.E., Real F.X., Cunningham-Rundles S., Myskowski P.L., Koziner B., Fein S., et al. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. The New England Journal of Medicine 1983, 308:1071-1076.
88. Krown S.E., Real F.X., Vadhan-Raj S., Cunningham-Rundles S., Krim M., Wong G., et al. Kaposi's sarcoma and the acquired immune deficiency syndrome. Treatment with recombinant interferon alpha and analysis of prognostic factors. Cancer 1986, 57:1662-1665.
89. Lane H.C., Kovacs J.A., Feinberg J., Herpin B., Davey V., Walker R., et al. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet 1988, 2:1218-1222.
90. Volberding P.A., Mitsuyasu R. Recombinant interferon alpha in the treatment of acquired immune deficiency syndrome-related Kaposi's sarcoma. Seminars in Oncology 1985, 12:2-6.
91. Adalid-Peralta L., Godot V., Colin C., Krzysiek R., Tran T., Poignard P., et al. Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection. Journal of Leukocyte Biology 2008, 83:1060-1067.
92. Berglund O., Engman K., Ehrnst A., Andersson J., Lidman K., Akerlund B., et al. Combined treatment of symptomatic human immunodeficiency virus type 1 infection with native interferon-alpha and zidovudine. The Journal of Infectious Diseases 1991, 163:710-715.
93. Davey R.T., Davey V.J., Metcalf J.A., Zurlo J.J., Kovacs J.A., Falloon J., et al. A phase I/II trial of zidovudine, interferon-alpha, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection. The Journal of Infectious Diseases 1991, 164:43-52.
94. Edlin B.R., Weinstein R.A., Whaling S.M., Ou C.Y., Connolly P.J., Moore J.L., et al. Zidovudine-interferon-alpha combination therapy in patients with advanced human immunodeficiency virus type 1 infection: biphasic response of p24 antigen and quantitative polymerase chain reaction. The Journal of Infectious Diseases 1992, 165:793-798.
95. Fernandez-Cruz E., Lang J.M., Frissen J., Furner V., Chateauvert M., Boucher C.A., et al. Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts>150×10(6)/L: results of the Zidon trial. Zidon Study Group. AIDS 1995, 9:1025-1035.
96. Kovacs J.A., Bechtel C., Davey R.T., Falloon J., Polis M.A., Walker R.E., et al. Combination therapy with didanosine and interferon-alpha in human immunodeficiency virus-infected patients: results of a phase I/II trial. The Journal of Infectious Diseases 1996, 173:840-848.
97. Krown S.E., Aeppli D., Balfour H.H. Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. HIV Protocol C91-253 Study Team. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology: Official Publication of the International Retrovirology Association 1999, 20:245-254.
98. Orholm M., Pedersen C., Mathiesen L., Dowd P., Nielsen J.O. Suppression of p24 antigen in sera from HIV-infected individuals with low-dose alpha-interferon and zidovudine: a pilot study. AIDS 1989, 3:97-100.
99. Haas D.W., Lavelle J., Nadler J.P., Greenberg S.B., Frame P., Mustafa N., et al. A randomized trial of interferon alpha therapy for HIV type 1 infection. AIDS Research and Human Retroviruses 2000, 16:183-190.
100. Lane H.C., Davey V., Kovacs J.A., Feinberg J., Metcalf J.A., Herpin B., et al. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Annals of Internal Medicine 1990, 112:805-811.
101. Skillman D.R., Malone J.L., Decker C.F., Wagner K.F., Mapou R.L., Liao M.J., et al. Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type 1 disease: evidence for drug safety, tolerance, and antiviral activity. The Journal of Infectious Diseases 1996, 173:1107-1114.
102. Hatzakis A., Gargalianos P., Kiosses V., Lazanas M., Sypsa V., Anastassopoulou C., et al. Low-dose IFN-alpha monotherapy in treatment-naive individuals with HIV-1 infection: evidence of potent suppression of viral replication. Journal of Interferon and Cytokine Research 2001, 21:861-869.
103. Emilie D., Burgard M., Lascoux-Combe C., Laughlin M., Krzysiek R., Pignon C., et al. Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study. AIDS 2001, 15:1435-1437.
104. Portales P., Reynes J., Pinet V., Rouzier-Panis R., Baillat V., Clot J., et al. Interferon-alpha restores HIV-induced alteration of natural killer cell perforin expression in vivo. AIDS 2003, 17:495-504.
105. Asmuth D.M., Murphy R.L., Rosenkranz S.L., Lertora J.J., Kottilil S., Cramer Y., et al. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. The Journal of Infectious Diseases 2010, 201:1686-1696.
106. May M.T., Sterne J.A., Costagliola D., Sabin C.A., Phillips A.N., Justice A.C., et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006, 368:451-458.
107. Rook A.H., Hooks J.J., Quinnan G.V., Lane H.C., Manischewitz J.F., Macher A.M., et al. Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism. Journal of Immunology 1985, 134:1503-1507.
108. Pett S.L., Kelleher A.D., Emery S. Role of interleukin-2 in patients with HIV infection. Drugs 2010, 70:1115-1130.
109. Durier C., Capitant C., Lascaux A.S., Goujard C., Oksenhendler E., Poizot-Martin I., et al. Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials). AIDS 2007, 21:1887-1897.
110. Read S.W., Lempicki R.A., Di Mascio M., Srinivasula S., Burke R., Sachau W., et al. CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients. The Journal of Infectious Diseases 2008, 198:843-850.
111. Abrams D., Levy Y., Losso M.H., Babiker A., Collins G., Cooper D.A., et al. Interleukin-2 therapy in patients with HIV infection. The New England Journal of Medicine 2009, 361:1548-1559.
112. Sellier P., Lafuente-Lafuente C., Bergmann J.F. Interleukin-2 therapy in patients with HIV infection. The New England Journal of Medicine 2010, 362:270-271. author reply 1.
113. Weiss L., Letimier F.A., Carriere M., Maiella S., Donkova-Petrini V., Targat B., et al. In vivo expansion of naive and activated CD4+CD25+FOXP3+ regulatory T cell populations in interleukin-2-treated HIV patients. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:10632-10637.
114. Fontas E., Kousignian I., Pradier C., Poizot-Martin I., Durier C., Weiss L., et al. IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy-results from the ANRS CO4 cohort. The Journal of Antimicrobial Chemotherapy 2010, 65:2215-2223.
115. Barbai V.H., Ujhelyi E., Szlavik J., Vietorisz I., Varga L., Fey E., et al. Changes in the levels of some acute-phase proteins in human immunodeficiency virus-1 infected patients, following interleukin-2 treatment. Clinical and Experimental Immunology 2010, 161:134-141.
116. Porter B.O., Shen J., Kovacs J.A., Davey R.T., Rehm C., Lozier J., et al. Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels. AIDS 2009, 23:2015-2019.
117. Read S.W., Ciccone E.J., Mannon P.J., Yao M.D., Chairez C.L., Davey R.T., et al. The effect of intermittent IL-2 therapy on CD4 T cells in the gut in HIV-1-infected patients. Journal of Acquired Immune Deficiency Syndromes 2011, 56:340-343.
118. Sabbatini F., Bandera A., Ferrario G., Trabattoni D., Marchetti G., Franzetti F., et al. Qualitative immune modulation by interleukin-2 (IL-2) adjuvant therapy in immunological non responder HIV-infected patients. PloS One 2010, 5:e14119.
119. Kinter A.L., Poli G., Fox L., Hardy E., Fauci A.S. HIV replication in IL-2-stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines. Journal of Immunology 1995, 154:2448-2459.
120. Chun T.W., Engel D., Mizell S.B., Hallahan C.W., Fischette M., Park S., et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nature Medicine 1999, 5:651-655.
121. Kulkosky J., Nunnari G., Otero M., Calarota S., Dornadula G., Zhang H., et al. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. The Journal of Infectious Diseases 2002, 186:1403-1411.
122. Stellbrink H.J., van Lunzen J., Westby M., O'Sullivan E., Schneider C., Adam A., et al. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS 2002, 16:1479-1487.
123. Youle M., Emery S., Fisher M., Nelson M., Fosdick L., Janossy G., et al. A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard Study. PLoS Clinical Trials 2006, 1:e3.
124. Tavel J.A., Babiker A., Fox L., Gey D., Lopardo G., Markowitz N., et al. Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study. PloS One 2010, 5:e9334.
125. Molina J.M., Levy Y., Fournier I., Hamonic S., Bentata M., Beck-Wirth G., et al. Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119). The Journal of Infectious Diseases 2009, 200:206-215.
126. Angus B., Lampe F., Tambussi G., Duvivier C., Katlama C., Youle M., et al. TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals. AIDS 2008, 22:737-740.
127. Porter B.O., Anthony K.B., Shen J., Hahn B., Keh C.E., Maldarelli F., et al. Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial. AIDS 2009, 23:203-212.
128. Bosch R.J., Pollard R.B., Landay A., Aga E., Fox L., Mitsuyasu R. A randomized trial of interleukin-2 during withdrawal of antiretroviral treatment. Journal of Interferon & Cytokine Research: The Official Journal of the International Society for Interferon and Cytokine Research 2011, 31:481-483.
129. Levy Y., Thiebaut R., Gougeon M.L., Molina J.M., Weiss L., Girard P.M., et al. Effect of intermittent interleukin-2 therapy on CD4+ T cell counts following antiretroviral cessation in patients with HIV (ANRS 118/NIH 04-I-0018 ILIADE Trial). AIDS 2012.
130. Napolitano L.A., Grant R.M., Deeks S.G., Schmidt D., De Rosa S.C., Herzenberg L.A., et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nature Medicine 2001, 7:73-79.
131. Fry T.J., Connick E., Falloon J., Lederman M.M., Liewehr D.J., Spritzler J., et al. A potential role for interleukin-7 in T-cell homeostasis. Blood 2001, 97:2983-2990.
132. Managlia E.Z., Landay A., Al-Harthi L. Interleukin-7 induces HIV replication in primary naive T cells through a nuclear factor of activated T cell (NFAT)-dependent pathway. Virology 2006, 350:443-452.
133. Smithgall M.D., Wong J.G., Critchett K.E., Haffar O.K. IL-7 up-regulates HIV-1 replication in naturally infected peripheral blood mononuclear cells. Journal of Immunology 1996, 156:2324-2330.
134. Beq S., Nugeyre M.T., Ho Tsong Fang R., Gautier D., Legrand R., Schmitt N., et al. IL-7 induces immunological improvement in SIV-infected rhesus macaques under antiviral therapy. Journal of Immunology 2006, 176:914-922.
135. Nugeyre M.T., Monceaux V., Beq S., Cumont M.C., Ho Tsong Fang R., Chene L., et al. IL-7 stimulates T cell renewal without increasing viral replication in simian immunodeficiency virus-infected macaques. Journal of Immunology 2003, 171:4447-4453.
136. Sportes C., Babb R.R., Krumlauf M.C., Hakim F.T., Steinberg S.M., Chow C.K., et al. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2010, 16:727-735.
137. Sportes C., Hakim F.T., Memon S.A., Zhang H., Chua K.S., Brown M.R., et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. The Journal of Experimental Medicine 2008, 205:1701-1714.
138. Wang F.X., Xu Y., Sullivan J., Souder E., Argyris E.G., Acheampong E.A., et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. The Journal of Clinical Investigation 2005, 115:128-137.
139. Levy Y., Lacabaratz C., Weiss L., Viard J.P., Goujard C., Lelievre J.D., et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. The Journal of Clinical Investigation 2009, 119:997-1007.
140. Imamichi H., Degray G., Asmuth D.M., Fischl M.A., Landay A.L., Lederman M.M., et al. HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy. AIDS 2011, 25:159-164.
141. Berard M., Brandt K., Bulfone-Paus S., Tough D.F. IL-15 promotes the survival of naive and memory phenotype CD8+ T cells. Journal of Immunology 2003, 170:5018-5026.
142. Surh C.D., Boyman O., Purton J.F., Sprent J. Homeostasis of memory T cells. Immunological Reviews 2006, 211:154-163.
143. Prlic M., Blazar B.R., Farrar M.A., Jameson S.C. In vivo survival and homeostatic proliferation of natural killer cells. The Journal of Experimental Medicine 2003, 197:967-976.
144. Forcina G., D'Ettorre G., Mastroianni C.M., Carnevalini M., Scorzolini L., Ceccarelli G., et al. Interleukin-15 modulates interferon-gamma and beta-chemokine production in patients with HIV infection: implications for immune-based therapy. Cytokine 2004, 25:283-290.
145. d'Ettorre G., Andreotti M., Carnevalini M., Andreoni C., Zaffiri L., Vullo V., et al. Interleukin-15 enhances the secretion of IFN-gamma and CC chemokines by natural killer cells from HIV viremic and aviremic patients. Immunology Letters 2006, 103:192-195.
146. Lum J.J., Schnepple D.J., Nie Z., Sanchez-Dardon J., Mbisa G.L., Mihowich J., et al. Differential effects of interleukin-7 and interleukin-15 on NK cell anti-human immunodeficiency virus activity. Journal of Virology 2004, 78:6033-6042.
147. d'Ettorre G., Andreotti M., Ceccarelli G., Galluzzo C.M., Mallano A., Massetti A.P., et al. The role of IL-15 in challenging Acquired Immunodeficiency Syndrome. Cytokine 2012, 57:54-60.
148. Steel J.C., Waldmann T.A., Morris J.C. Interleukin-15 biology and its therapeutic implications in cancer. Trends in Pharmacological Sciences 2012, 33:35-41.
149. Leone A., Picker L.J., Sodora D.L. IL-2, IL-7 and IL-15 as immuno-modulators during SIV/HIV vaccination and treatment. Current HIV Research 2009, 7:83-90.
150. Hilleman M.R. Immunologic, chemotherapeutic and interferon approaches to control of viral disease. American Journal of Medicine 1965, 38:751-766.
151. Grob P.J., Joller-Jemelka H.I., Binswanger U., Zaruba K., Descoeudres C., Fernex M. Interferon as an adjuvant for hepatitis B vaccination in non- and low-responder populations. European Journal of Clinical Microbiology 1984, 3:195-198.
152. Quiroga J.A., Castillo I., Porres J.C., Casado S., Saez F., Gracia Martinez M., et al. Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. Hepatology 1990, 12:661-663.
153. Merigan T.C. Is recombinant interleukin-2 the best way to deliver interferon-gamma in human disease?. Journal of Interferon Research 1987, 7:635-639.
154. Wiryana P., Bui T., Faltynek C.R., Ho R.J. Augmentation of cell-mediated immunotherapy against herpes simplex virus by interleukins: comparison of in vivo effects of IL-2 and IL-7 on adoptively transferred T cells. Vaccine 1997, 15:561-563.
155. Serafini P., Carbley R., Noonan K.A., Tan G., Bronte V., Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Research 2004, 64:6337-6343.
156. Kusakabe K., Xin K.Q., Katoh H., Sumino K., Hagiwara E., Kawamoto S., et al. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. Journal of Immunology 2000, 164:3102-3111.
157. Ahlers J.D., Dunlop N., Alling D.W., Nara P.L., Berzofsky J.A. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. Journal of Immunology 1997, 158:3947-3958.
158. Barouch D.H., Santra S., Steenbeke T.D., Zheng X.X., Perry H.C., Davies M.E., et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. Journal of Immunology 1998, 161:1875-1882.
159. Desrosiers R.C., Wyand M.S., Kodama T., Ringler D.J., Arthur L.O., Sehgal P.K., et al. Vaccine protection against simian immunodeficiency virus infection. Proceedings of the National Academy of Sciences of the United States of America 1989, 86:6353-6357.
160. Barouch D.H., Craiu A., Kuroda M.J., Schmitz J.E., Zheng X.X., Santra S., et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:4192-4197.
161. Barouch D., Santra S., Schmitz J., Kuroda M., Fu T., Wagner W., et al. Control of viremia and prevention of clinical AIDS in Rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000, 290:486-492.
162. Villinger F., Miller R., Mori K., Mayne A.E., Bostik P., Sundstrom J.B., et al. IL-15 is superior to IL-2 in the generation of long-lived antigen specific memory CD4 and CD8 T cells in rhesus macaques. Vaccine 2004, 22:3510-3521.
163. Chong S.Y., Egan M.A., Kutzler M.A., Megati S., Masood A., Roopchard V., et al. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. Vaccine 2007, 25:4967-4982.
164. Hryniewicz A., Price D.A., Moniuszko M., Boasso A., Edghill-Spano Y., West S.M., et al. Interleukin-15 but not interleukin-7 abrogates vaccine-induced decrease in virus level in simian immunodeficiency virus mac251-infected macaques. Journal of Immunology 2007, 178:3492-3504.
165. Sui Y., Gagnon S., Dzutsev A., Zhu Q., Yu H., Hogg A., et al. TLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4 memory T cell loss in SIVmac251-challenged rhesus macaques. Vaccine 2011, 30:59-68.
166. Sykes K.F., Lewis M.G., Squires B., Johnston S.A. Evaluation of SIV library vaccines with genetic cytokines in a macaque challenge. Vaccine 2002, 20:2382-2395.
167. O'Neill E., Martinez I., Villinger F., Rivera M., Gascot S., Colon C., et al. Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration. Journal of Medical Primatology 2002, 31:217-227.
168. Boyer J.D., Robinson T.M., Kutzler M.A., Parkinson R., Calarota S.A., Sidhu M.K., et al. SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. Journal of Medical Primatology 2005, 34:262-270.
169. Schadeck E.B., Sidhu M., Egan M.A., Chong S.Y., Piacente P., Masood A., et al. A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine 2006, 24:4677-4687.
170. Halwani R., Boyer J.D., Yassine-Diab B., Haddad E.K., Robinson T.M., Kumar S., et al. Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA + IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques. Journal of Immunology 2008, 180:7969-7979.
171. Winstone N., Wilson A.J., Morrow G., Boggiano C., Chiuchiolo M.J., Lopez M., et al. Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen. Journal of Virology 2011, 85:9578-9587.
172. Lai L., Vodros D., Kozlowski P.A., Montefiori D.C., Wilson R.L., Akerstrom V.L., et al. GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology 2007, 369:153-167.
173. Dubie R.A., Maksaereekul S., Shacklett B.L., Lemongello D., Cole K.S., Villinger F., et al. Co-immunization with IL-15 enhances cellular immune responses induced by a vif-deleted simian immunodeficiency virus proviral DNA vaccine and confers partial protection against vaginal challenge with SIVmac251. Virology 2009, 386:109-121.
174. Eberly M.D., Kader M., Hassan W., Rogers K.A., Zhou J., Mueller Y.M., et al. Increased IL-15 production is associated with higher susceptibility of memory CD4 T cells to simian immunodeficiency virus during acute infection. Journal of Immunology 2009, 182:1439-1448.
175. Staats H.F., Ennis F.A. IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens. Journal of Immunology 1999, 162:6141-6147.
176. Xin K.Q., Hamajima K., Sasaki S., Tsuji T., Watabe S., Okada E., et al. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine 1999, 17:858-866.
177. Spearman P., Kalams S., Elizaga M., Metch B., Chiu Y.L., Allen M., et al. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine 2009, 27:243-249.
178. Baden L.R., Blattner W.A., Morgan C., Huang Y., Defawe O.D., Sobieszczyk M.E., et al. Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects. Journal of Infectious Diseases 2011, 204:1541-1549.
179. Monsuez J.J., Escaut L., Teicher E., Charniot J.C., Vittecoq D. Cytokines in HIV-associated cardiomyopathy. International Journal of Cardiology 2007, 120:150-157.
180. Sevigny J.J., Albert S.M., McDermott M.P., McArthur J.C., Sacktor N., Conant K., et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004, 63:2084-2090.
181. Gibellini D., De Crignis E., Ponti C., Cimatti L., Borderi M., Tschon M., et al. HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. Journal of Medical Virology 2008, 80:1507-1514.
182. Nolting T., Lindecke A., Hartung H.P., Koutsilieri E., Maschke M., Husstedt I.W., et al. Cytokine levels in CSF and neuropsychological performance in HIV patients. Journal of Neurovirology 2012, 18(3):157-161.
183. Zietz C., Hotz B., Sturzl M., Rauch E., Penning R., Lohrs U. Aortic endothelium in HIV-1 infection: chronic injury, activation, and increased leukocyte adherence. The American Journal of Pathology 1996, 149:1887-1898.
184. Breen E.C., Hussain S.K., Magpantay L., Jacobson L.P., Detels R., Rabkin C.S., et al. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2011, 20:1303-1314.
185. Airoldi M., Bandera A., Trabattoni D., Tagliabue B., Arosio B., Soria A., et al. Neurocognitive impairment in HIV-infected naive patients with advanced disease: the role of virus and intrathecal immune activation. Clinical & Developmental Immunology 2012, 2012:467154.
186. Zamboni G., Antoniazzi F., Bertoldo F., Lauriola S., Antozzi L., Tato L. Altered bone metabolism in children infected with human immunodeficiency virus. Acta Paediatrica 2003, 92:12-16.
187. Ross M.J., Fan C., Ross M.D., Chu T.H., Shi Y., Kaufman L., et al. HIV-1 infection initiates an inflammatory cascade in human renal tubular epithelial cells. Journal of Acquired Immune Deficiency Syndromes 2006, 42:1-11.
188. Breen E.C., Boscardin W.J., Detels R., Jacobson L.P., Smith M.W., O'Brien S.J., et al. Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592C/C genotype. Clinical Immunology 2003, 109:119-129.
189. Raeburn C.D., Calkins C.M., Zimmerman M.A., Song Y., Ao L., Banerjee A., et al. ICAM-1 and VCAM-1 mediate endotoxemic myocardial dysfunction independent of neutrophil accumulation. American Journal of Physiology Regulatory, Integrative and Comparative Physiology 2002, 283:R477-R486.
190. Boring L., Gosling J., Cleary M., Charo I.F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998, 394:894-897.
191. Bernasconi S., Cinque P., Peri G., Sozzani S., Crociati A., Torri W., et al. Selective elevation of monocyte chemotactic protein-1 in the cerebrospinal fluid of AIDS patients with cytomegalovirus encephalitis. Journal of Infectious Diseases 1996, 174:1098-1101.
192. Ruff K.R., Puetter A., Levy L.S. Growth regulation of simian and human AIDS-related non-Hodgkin's lymphoma cell lines by TGF-beta1 and IL-6. BMC Cancer 2007, 7:35.
193. Rallon N.I., Barreiro P., Soriano V., Garcia-Samaniego J., Lopez M., Benito J.M. Elevated TGF-beta1 levels might protect HCV/HIV-coinfected patients from liver fibrosis. European Journal of Clinical Investigation 2011, 41:70-76.
194. Yamamoto T., Noble N.A., Miller D.E., Gold L.I., Hishida A., Nagase M., et al. Increased levels of transforming growth factor-beta in HIV-associated nephropathy. Kidney International 1999, 55:579-592.
195. Veldkamp C.T., Ziarek J.J., Su J., Basnet H., Lennertz R., Weiner J.J., et al. Monomeric structure of the cardioprotective chemokine SDF-1/CXCL12. Protein Science 2009, 18:1359-1369.
196. Singh K.K., Barroga C.F., Hughes M.D., Chen J., Raskino C., McKinney R.E., et al. Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV-1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infection. Journal of Infectious Diseases 2003, 188:1461-1472.
197. Baker B.J., Park K.W., Qin H., Ma X., Benveniste E.N. IL-27 inhibits OSM-mediated TNF-alpha and iNOS gene expression in microglia. Glia 2010, 58:1082-1093.
198. Sereti I., Dunham R.M., Spritzler J., Aga E., Proschan M.A., Medvik K., et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009, 113:6304-6314.